The approval of a disease-modifying therapy for early-stage Parkinson’s Disease (PD) and related neurodegenerative conditions stands to deliver far-reaching societal benefits.
At Performance Medical Technologies (PMT), our mission is not only to advance science but to reshape the future for patients, caregivers, healthcare systems, and economies around the world.
A validated, approved clinical therapy for early-stage Parkinson’s has the potential to:
Slowing disease progression can extend the productive, independent years of life for patients—reducing the need for assisted care and improving workforce retention.
In Italy and the U.S., the majority of care for PD patients is provided by unpaid family members. Effective early treatment reduces physical, emotional, and financial strain on millions of caregivers.
Delaying progression means fewer hospitalizations, reduced medication load, and less use of high-cost services such as nursing facilities and neurosurgical interventions.
In research-active regions like FVG and Virginia, the development and deployment of new therapies creates high-skilled jobs, stimulates biotech innovation clusters and attracts clinical trial investment and medical tourism.
Parkinson’s Disease is the fastest-growing neurological condition in the world, with profound consequences on quality of life, healthcare spending, and caregiver burden:
PMT’s work goes beyond the lab. We are committed to creating a ripple effect of impact—starting with the patient, extending to families, and transforming entire healthcare systems.
By bringing a safe, effective, and accessible treatment for early-stage Parkinson’s to market, we aim to:
The cost of inaction is immense—but the opportunity for meaningful change is greater. At PMT, we believe that scientific innovation can and must serve the greater good.
Together, we can change the trajectory of neurodegenerative disease—not just for individuals, but for society as a whole.
